Cellular & Molecular Intelligence
Smart Biology for Drug Discovery
Overview
Research published in Cellular & Molecular Intelligence spans all areas of pharmaceutical and therapeutic inquiry, including medicinal chemistry, pharmacology, pharmaceutics, pharmaceutical analysis, experimental and clinical medicine, biotechnology, microbiology, immunology, and systems pharmacology. The journal seeks to promote international collaboration, encourage interdisciplinary integration, and accelerate the translation of molecular intelligence into human health advancement.
CMI reflects the accelerating convergence of computational and biological innovation that is transforming modern medicine. We focus on studies that address fundamental mechanisms of disease pathogenesis and use data-driven or AI-assisted strategies to guide discovery and therapeutic design.
Editor-in-Chief
Not specified
Not specified
Journal information
Electronic ISSN
2345-2982
Abstracted and indexed in
Copyrigt @ 2025 editorypress
Computational & Artificial Intelligence in Biology
Foundation Models for Biology: Large-scale language models for proteins, RNA, and genomic architecture.
Agentic AI & Autonomous Labs: AI systems that autonomously design and execute wet-lab experiments.
Drug Design and Discovery: Generative AI for molecule synthesis, target prediction, high-throughput screening, ADME/Tox studies, combinatorial chemistry, and ligand interaction and validation.
Molecular Pharmacology: Genomics, proteomics, pharmacogenomics, and biomarker discovery.
Cellular Decision-Making & Intelligence
Biological Logic Gates: How cells integrate complex cues to choose between apoptosis, proliferation, or differentiation.
Immune Intelligence: Molecular foundations of immune memory and adaptive responses.
Neuro-Molecular Networks: Intelligence at the interface of neuronal signaling and molecular regulation.
Systems Biology & Multi-Omics Integration
Digital Twins: Multi-scale modeling of cells and organs to predict disease and treatment response.
Spatial Intelligence: Spatial omics revealing how tissue architecture shapes cellular function.
Network Pharmacology: Deep learning approaches to map protein-protein and gene-regulatory networks.
Programmable & Synthetic Therapeutics
CRISPR & Beyond: AI-optimized genome and epigenome editing technologies.
Molecular Robotics: Smart nanosystems for site-specific delivery of therapeutic payloads.
Synthetic Circuitry: Engineered biological “computers” for diagnostic and therapeutic functions.
Diseases and Application Areas
Gene and cell therapies
Clinical and functional genomics
Regenerative and high-definition medicine
Early disease diagnosis and precision health
Microbiome and environmental health
Cancer, cardiovascular, metabolic, and autoimmune diseases
Aging and neurodegenerative diseases
Infectious and inflammatory disorders
Policy of Cellular & Molecular Intelligence
1. Overview and Scope
Cellular & Molecular Intelligence (CMI) is an international, peer‑reviewed scholarly journal committed to publishing high‑quality research at the interface of cell biology, molecular medicine, computational biology, artificial intelligence, and translational biomedical sciences. The journal upholds the highest standards of editorial independence, scientific rigor, transparency, and research integrity. CMI’s editorial policies are aligned with and guided by the recommendations of the International Committee of Medical Journal Editors (ICMJE), the World Association of Medical Editors (WAME), and the Committee on Publication Ethics (COPE). Submission of a manuscript to CMI implies that all authors have read and agreed to its content, approve its submission, and confirm compliance with all journal policies.
2. Editorial Independence
Editorial decisions at CMI are based solely on scientific merit, originality, methodological rigor, and relevance to the journal’s scope. Editors operate independently of publishers, sponsors, advertisers, and funders. The journal endorses the WAME Policy Statement on Geopolitical Intrusion on Editorial Decisions and does not permit discrimination based on nationality, institutional affiliation, gender, ethnicity, or political considerations.
3. Peer‑Review Policy
CMI employs a single‑blind peer‑review model in which reviewer identities are concealed from authors. Each manuscript is evaluated by a minimum of two independent experts selected on the basis of subject expertise, absence of conflicts of interest, and ability to provide objective, constructive, and timely assessments. The editorial decision process is transparent and evidence‑based, and may include additional reviews or statistical assessment when required. All submissions are screened using plagiarism‑detection software prior to peer review. The journal strives to maintain an efficient review process, with an average initial decision timeline of approximately three to five weeks, while ensuring review quality and integrity.
4. Ethics and Research Integrity
CMI maintains zero tolerance for plagiarism, data fabrication, data falsification, image manipulation, or any form of research misconduct. All research must be conducted in accordance with internationally accepted ethical standards. Studies involving human participants must comply with the Declaration of Helsinki and must have prior approval from an appropriate ethics committee, with documented informed consent. Research involving animals must adhere to institutional, national, or international guidelines, including ARRIVE and relevant animal welfare regulations. Clinical trials must be prospectively registered in a publicly accessible registry. Manuscripts that do not meet ethical requirements may be rejected at any stage of the editorial process.
5. Authorship and Contributor Responsibilities
Authorship in CMI is based on the ICMJE criteria, requiring substantial contributions to study conception or design, data acquisition or analysis, manuscript drafting or critical revision, final approval of the published version, and accountability for all aspects of the work. The corresponding author is responsible for ensuring that all listed authors meet authorship criteria and that no eligible contributors are omitted. Any changes to authorship before acceptance require written consent from all authors; changes after acceptance are not permitted except under exceptional circumstances and with editorial approval. Contributors who do not qualify for authorship must be acknowledged appropriately.
6. Artificial Intelligence and Computational Research Policy
Given the journal’s scope, CMI places special emphasis on transparency and responsibility in AI‑driven and computational research. Authors must disclose all AI, machine learning, and computational tools used, including software names, versions, algorithms, and datasets. Manuscripts must include sufficient methodological detail to enable reproducibility, including model architecture, training and validation strategies, performance metrics, and limitations. Undisclosed AI‑generated data, images, or text are not permitted. Human oversight is mandatory for AI‑assisted analyses and manuscript preparation, and authors retain full responsibility for the integrity and accuracy of the work.
7. Data Availability and Reproducibility
CMI strongly supports open science and reproducibility. Authors are required to include an “Availability of Data and Materials” section describing where and how the data supporting the findings can be accessed. Whenever possible, data should be deposited in recognized public repositories, with accession numbers or persistent identifiers provided. Where data cannot be shared, authors must clearly justify the restriction. The journal encourages adherence to FAIR (Findable, Accessible, Interoperable, Reusable) data principles and requires appropriate citation of publicly available datasets.
8. Conflict of Interest Policy
All authors must disclose any financial or non‑financial conflicts of interest that could influence the interpretation or presentation of their work. Funding sources, institutional affiliations, consultancies, stock ownership, patents, or personal relationships must be transparently declared. Editors and reviewers are also required to disclose conflicts of interest and will be recused from handling manuscripts where a conflict exists.
9. Funding and Acknowledgements
All sources of funding must be clearly disclosed, including grant numbers and funding agencies. The role of funders in study design, data collection, analysis, interpretation, and publication decisions must be explicitly stated. Editorial decisions are independent of funding considerations. Individuals or organizations that contributed to the work but do not meet authorship criteria should be acknowledged appropriately.
10. Open Access and Copyright
CMI operates under an open-access publishing model to ensure global dissemination of research. Articles are published under a Creative Commons license, preferably CC‑BY, allowing unrestricted use, distribution, and reproduction provided the original work is properly cited. Authors retain copyright to their work unless otherwise stated.
11. Preprints and Prior Publication
CMI permits submission of manuscripts previously posted on recognized preprint servers such as bioRxiv, medRxiv, or arXiv. Authors must disclose any prior dissemination, including conference abstracts, theses, or institutional repositories. Prior posting does not prejudice editorial consideration, provided the manuscript represents original work and proper transparency is maintained.
12. Corrections, Retractions, and Expressions of Concern
To maintain the integrity of the scholarly record, CMI follows COPE guidelines for issuing corrections, retractions, or expressions of concern. Errors that do not invalidate the findings may be corrected through an erratum, while serious ethical violations or unreliable findings may result in retraction. Retraction notices remain permanently available and linked to the original article.
13. Plagiarism and Similarity Policy
All submissions undergo plagiarism screening prior to peer review. Manuscripts with unacceptable similarity, including self‑plagiarism and redundant publication, will be rejected. Confirmed cases of plagiarism after publication may result in retraction and notification of authors’ institutions or funding agencies. The journal considers full plagiarism, partial plagiarism, and self‑plagiarism as serious breaches of publication ethics.
14. Appeals and Complaints
Authors may appeal editorial decisions by submitting a detailed, point‑by‑point rebuttal addressing technical or factual concerns. Appeals are evaluated by senior editors independent of the original decision. Complaints regarding editorial processes, peer review, or ethical concerns are handled in accordance with COPE standards.
15. Confidentiality
All manuscripts submitted to CMI are treated as confidential documents. Editors and reviewers must not disclose, share, or use unpublished material for personal advantage. Reviewers may not cite or reuse data from manuscripts under review without explicit permission from the authors and the journal.
16. Advertising, Sponsorship, and Commercial Influence
CMI maintains a strict separation between editorial content and advertising or sponsorship. Advertisers and sponsors have no influence over editorial decisions, peer review, or publication outcomes. The journal does not publish advertorial or promotional content.
17. Diversity, Equity, and Inclusion
CMI is committed to promoting diversity, equity, and inclusion in editorial practices, peer review, and authorship. The journal fosters a fair and unbiased review process and actively supports gender, geographic, and disciplinary diversity across its editorial board, reviewer pool, and published content.
18. Policy Review and Updates
These policies are reviewed periodically to ensure alignment with evolving best practices in scholarly publishing, ethics, and open science. Updates will be communicated transparently on the journal’s website.
No articles published yet.
Guide for Authors
About the Journal and Scope
Cellular & Molecular Intelligence (CMI) is an international, peer‑reviewed open‑access journal publishing original research and scholarly work across pharmaceutical and therapeutic sciences, including medicinal chemistry, pharmacology, pharmaceutical analysis, pharmaceutics, pharmaceutical administration, and experimental and clinical therapeutics. Studies in drug‑related fields such as biology, biochemistry, physiology, microbiology, immunology, molecular medicine, and systems/AI‑driven biomedicine are also within the journal’s scope.
All manuscripts must be original, not under consideration elsewhere, and prepared in accordance with ICMJE and relevant reporting guidelines.
Article Types and Length Limits
CMI publishes the following article types, each with specific structure and limits (word counts exclude references):
Original Research Articles
Scope: Full‑length reports of novel experimental, computational, translational, or clinical studies of clear significance to the field.
Structure: Title page, Abstract, Keywords, Introduction, Materials and Methods, Results, Discussion, Conclusions (optional), Acknowledgments, References, Tables, Figures.
Limits: Up to 12,000 words; ≤ 100 references; ≤ 10 combined figures and tables
Supplementary data allowed for non‑essential but supportive material (e.g., unedited blots, raw data files, extended methods).
Brief Reports / Short Communications
Scope: Concise reports that definitively document important experimental findings or clinically informative observations; not for preliminary or incomplete data.
Structure: As for Original Articles, but Results and Discussion are combined into a single section.
Limits: Up to 3,000 words; ≤ 30 references; ≤ 4 figures and/or tables.
Review Articles and Mini‑Reviews
Scope: Comprehensive, critical, and balanced overviews of recent advances; systematic reviews are encouraged to follow PRISMA or appropriate reporting guidelines.
Standard Reviews: Up to 15,000 words; ≤ 200 references; ≤ 10 figures and/or tables.
Mini‑Reviews: Up to 4,000 words; ≤ 50 references; ≤ 5 figures and/or tables.
Methods & Protocols
Scope: Detailed descriptions of experimental, computational, or AI/ML protocols enabling reproducibility and broad reuse.
Recommended content: Rationale, step‑by‑step procedures, critical parameters, troubleshooting, validation data.
Typical limits: Up to 4,000 words; ≤ 40 references; ≤ 6 figures and/or tables, plus protocol checklists or code as supplementary material.
AI/Computational Models & Resources
Scope: New algorithms, models, datasets, software tools, or computational pipelines relevant to cellular, molecular, pharmaceutical, or translational research.
Requirements: Clear description of model architecture, datasets, training/validation strategy, performance metrics, benchmarking, and limitations; code and/or models should be made publicly available where possible.
Typical limits: Up to 5,000 words; ≤ 60 references; ≤ 8 figures and/or tables.
Case Reports
Scope: Detailed reports describing novel, rare, or instructive clinical cases, including unusual therapeutic responses, mechanisms, or adverse drug reactions.
Content: Patient demographics, history, presentation, investigations, diagnosis, management, outcome, and learning points; written informed consent is mandatory for identifiable cases.
Limits: Up to 3,000 words; Typically ≤ 20 references; Figures (e.g., images) as justified by the case.
Perspectives / Commentaries
Scope: Opinion pieces that offer expert perspectives on emerging concepts, methods, policies, or controversies relevant to CMI’s scope.
Limits: Up to 3,000 words; ≤ 30 references; ≤ 3 figures and/or tables.
Communications (Comments / Correspondence)
Scope: Short, timely discussions of recently published CMI articles, emerging findings, or policy issues of immediate relevance.
Limits: Up to 1,500 words; ≤ 20 references; ≤ 2 figures and/or tables.
Editorials (by Invitation)
Scope: Invited commentaries providing context for articles or issues of high current interest.
Limits: Up to 1,000 words; ≤ 10 references; One figure or table.
Manuscript Preparation
General Formatting
File format: Microsoft Word (.doc or .docx) or compatible word‑processing format.
Language: Clear, grammatically correct English; British or American spelling is acceptable if used consistently.
Layout: Font: 12‑point standard font (e.g., Times New Roman, Arial).
Margins: 1 inch (2.5 cm) on all sides.
Line spacing: 1.5–double spacing is recommended to facilitate review.
Page numbers: Include continuous page numbering.
Where applicable, authors are encouraged to follow discipline‑specific reporting guidelines (e.g., CONSORT, STROBE, PRISMA, ARRIVE) via the EQUATOR Network.
Manuscript Sections (Standard Research Articles)
Unless otherwise specified under the article type, manuscripts should be organized as follows:
Title Page
Abstract and Keywords
Main Text (Introduction, Materials and Methods, Results, Discussion, Conclusions)
Acknowledgments
Ethical Compliance Statement
Conflict of Interest and Funding Statements
Data Availability Statement
References
Tables and Figures (with legends)
Supplementary Materials (if any).
Title Page
Full article title (concise, informative; avoid non‑standard abbreviations).
Full names, institutional affiliations, and ORCID IDs (where available) for all authors.
Corresponding author’s email address, full postal address, and telephone (optional).
Short running title (≤ 50 characters).
Article type (e.g., Original Research, Review).
Abstract
Length: ≤ 250 words.
Structure (recommended for Original Articles): Background, Methods, Results, Conclusions; other article types may use a single unstructured paragraph.
Avoid citations, abbreviations, and undefined acronyms.
Keywords
Provide 4–6 keywords or phrases, ideally using terms from MeSH or other recognized vocabularies where relevant.
Introduction
Briefly summarize the background and knowledge gap, clearly state the objective(s) and hypothesis, and explain the significance of the work.
Materials and Methods
Provide sufficient detail to allow independent reproduction of the work.
Clearly describe:
Study design, setting, and participants/samples.
Inclusion/exclusion criteria (for human or animal studies).
Reagents, materials, and instruments (including manufacturer, city, country).
Statistical and computational methods, including software and version.
Previously published methods should be cited and briefly summarized; novel modifications must be described.
For case reports, replace this section with “Case Presentation,” including clinical history, findings, diagnostics, interventions, and follow‑up.
Results
Present results clearly and concisely, using tables and figures to avoid redundancy.
Provide appropriate statistical indicators (effect sizes, confidence intervals, P‑values) where applicable.
Discussion
Interpret findings in the context of existing literature, strengths and limitations, and implications for research and practice.
Avoid repeating detailed results.
Conclusions
Provide a focused, evidence‑based summary of the main findings, their significance, and, where appropriate, actionable implications.
Acknowledgments
Acknowledge individuals, institutions, or organizations that contributed to the work but do not qualify for authorship (e.g., technical support, editorial assistance).
Confirm that acknowledged individuals have consented to be named where applicable.
Ethical Compliance
Human participants: Include statements about ethics committee approval, protocol number, and informed consent, in line with the Declaration of Helsinki.
Animals: State adherence to relevant guidelines (e.g., institutional, national, ARRIVE).
Clinical trials: Provide registry name and registration number.
Conflict of Interest and Funding
Provide a clear Conflict of Interest statement describing any financial or non‑financial competing interests.
Provide a Funding statement specifying funders, grant numbers, and the role (if any) of funders in study design, data collection, analysis, and publication decision.
Data Availability Statement
Describe where and how data, code, and materials can be accessed (e.g., public repository, upon reasonable request).
Where data cannot be shared, provide a brief rationale (e.g., privacy, legal restrictions).
References
Use a consistent reference style as specified on the journal website (e.g., Vancouver or AMA); ensure completeness and accuracy of all citations.
All references cited in the text must appear in the reference list and vice versa.
Tables and Figures
Number tables and figures consecutively in the order of appearance (Table 1, Figure 1, etc.).
Provide clear, self‑contained titles and legends; explain all abbreviations.
Ensure adequate resolution for images and graphics (see journal website for minimum DPI).
Supplementary Materials
Provide datasets, extended methods, code, videos, or additional figures as separate files, clearly labeled and referenced in the main text.
Supplementary content should support but not be essential to understanding the primary article.
Special Requirements for AI, Computational, and Case‑Based Work
AI and Computational Studies
For AI/ML and computational manuscripts, authors must:
Describe datasets (source, preprocessing, inclusion/exclusion), model architecture, training/validation splits, and performance metrics.
Disclose all AI tools used for analysis or writing assistance, with versions and providers.
Provide access to code, models, and benchmark data where feasible, or justify restrictions.
Case Reports and Case‑Based Studies
Confirm written informed consent for publication; mask identifying details unless essential and consented.
Emphasize clinical reasoning, mechanistic insight, and educational value, rather than simple narrative description.
Manuscript Submission and Workflow
Preparing Your Submission Package
Authors should prepare and upload the following:
Cover letter: Briefly describe the novelty, importance, fit with CMI, and any relevant ethical or data issues.
Main manuscript file
Title page (containing all information).
Figures and tables: Embedded in the text and/or uploaded as separate high‑resolution files.
Supplementary materials: Uploaded as separate, clearly labeled files.
If images and tables are submitted separately, they may be compressed in a single .zip archive before upload.
Online Submission
Manuscripts must be submitted via the journal’s online submission system (https://editorypress.uz).
Ensure all metadata (author names, affiliations, abstract, keywords, funding, conflicts) are accurately completed during submission.
Editorial and Peer‑Review Process
A typical process includes:
Initial editorial assessment for scope, formatting, and ethical compliance.
Plagiarism screening using similarity‑detection software.
Single‑blind peer review by at least two independent experts, plus statistical review when needed.
Editorial decision (accept, minor revision, major revision, reject).
Revision and possible re‑review.
Final acceptance, copyediting, typesetting, proofs, and online publication with DOI.
Authors must carefully review and approve proofs; only minor corrections are allowed at this stage.
Open Access, Charges, and Licensing
CMI operates a fully open‑access model: articles are free to read and, under the selected Creative Commons license (preferably CC BY), free to reuse with appropriate attribution. The journal aims to minimize or waive article processing charges (APCs) wherever possible and will state any applicable fees transparently on the website.
Final Checks Before Submission
Before submitting, authors should confirm that:
The manuscript fits CMI’s scope and selected article type.
All authors approve the final version and agree to submission.
The work complies with ethical, reporting, and data‑sharing requirements.
The text is clear, consistent, and has been thoroughly proofread.
All figures, tables, and supplementary files are correctly labeled and cited in the text.
No journal updates yet.